Monte Rosa Therapeutics, Inc. (GLUE) has a negative trailing P/E of -29.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -3.39%.
Criteria proven by this page:
Overall SharesGrow Score: 66/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -116.3 | 0.00 | -76.72 | 0.00 | - |
| 2020 | -26.0 | -0.07 | -19.13 | 0.00 | - |
| 2021 | -12.8 | -0.14 | 2.73 | 0.00 | - |
| 2022 | -3.3 | -0.07 | 1.32 | 0.00 | - |
| 2023 | -2.1 | -0.15 | 1.62 | 0.00 | - |
| 2024 | -7.1 | 0.11 | 2.30 | 6.78 | - |
| 2025 | -33.7 | 0.64 | 5.59 | 10.53 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.18 | $0.00 | $-8.02M | - |
| 2020 | $-0.82 | $0.00 | $-36.07M | - |
| 2021 | $-1.55 | $0.00 | $-71.94M | - |
| 2022 | $-2.22 | $0.00 | $-104.62M | - |
| 2023 | $-2.63 | $0.00 | $-135.35M | - |
| 2024 | $-0.98 | $75.62M | $-72.7M | -96.1% |
| 2025 | $-0.46 | $123.67M | $-38.63M | -31.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.50 | $-2.26 – $-0.16 | $56.75M | $17.78M – $117.04M | 5 |
| 2027 | $-1.69 | $-2.97 – $0.71 | $71.75M | $23.51M – $168.22M | 5 |
| 2028 | $-1.99 | $-2.90 – $-0.10 | $39.03M | $12.55M – $86.77M | 5 |
| 2029 | $-1.81 | $-4.69 – $-0.21 | $123.44M | $39.68M – $274.41M | 1 |
| 2030 | $-1.31 | $-3.39 – $-0.15 | $179.45M | $57.69M – $398.91M | 1 |
